Insider Trading Alert - BIIB, CTBI And ENSG Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 16, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $442.00 to $2,999,379.00.

Highlighted Stocks Traded by Insiders:

Biogen (BIIB) - FREE Research Report

Posner Brian S, who is Director at Biogen, sold 400 shares at $386.64 on June 16, 2015. Following this transaction, the Director owned 5,745 shares meaning that the stake was reduced by 6.51% with the 400-share transaction.

The shares most recently traded at $390.78, up $4.14, or 1.06% since the insider transaction. Historical insider transactions for Biogen go as follows:

  • 4-Week # shares sold: 1,362
  • 12-Week # shares sold: 11,460
  • 24-Week # shares sold: 23,551

The average volume for Biogen has been 1.8 million shares per day over the past 30 days. Biogen has a market cap of $91.3 billion and is part of the health care sector and drugs industry. Shares are up 14.38% year-to-date as of the close of trading on Tuesday.

Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. The company has a P/E ratio of 28.1. Currently, there are 10 analysts who rate Biogen a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIIB - FREE

TheStreet Quant Ratings rates Biogen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Biogen Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Community Trust Bancorp (CTBI) - FREE Research Report

Ramsey James R, who is Director at Community Trust Bancorp, bought 400 shares at $34.14 on June 16, 2015. Following this transaction, the Director owned 10,725 shares meaning that the stake was boosted by 3.87% with the 400-share transaction.

The shares most recently traded at $34.43, up $0.29, or 0.83% since the insider transaction. Historical insider transactions for Community Trust Bancorp go as follows:

  • 4-Week # shares bought: 400
  • 4-Week # shares sold: 2,348
  • 12-Week # shares bought: 400
  • 12-Week # shares sold: 7,541
  • 24-Week # shares bought: 400
  • 24-Week # shares sold: 7,541

The average volume for Community Trust Bancorp has been 31,800 shares per day over the past 30 days. Community Trust Bancorp has a market cap of $594.5 million and is part of the financial sector and banking industry. Shares are down 7.13% year-to-date as of the close of trading on Tuesday.

Community Trust Bancorp, Inc. operates as a bank holding company of Community Trust Bank, Inc. and Community Trust and Investment Company that provides commercial and personal banking, and trust and wealth management services to small and mid-sized communities. The stock currently has a dividend yield of 3.53%. The company has a P/E ratio of 13.4. Currently, there are no analysts who rate Community Trust Bancorp a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CTBI - FREE

TheStreet Quant Ratings rates Community Trust Bancorp as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, growth in earnings per share and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Community Trust Bancorp Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ensign Group (ENSG) - FREE Research Report

Snapper Suzanne D., who is Cfo at Ensign Group, sold 89 shares at $50.12 on June 16, 2015. Following this transaction, the Cfo owned 38,618 shares meaning that the stake was reduced by 0.23% with the 89-share transaction.

Keetch Chad, who is Executive Vice President at Ensign Group, sold 91 shares at $49.57 on June 16, 2015. Following this transaction, the Executive Vice President owned 13,596 shares meaning that the stake was reduced by 0.66% with the 91-share transaction.

The shares most recently traded at $51.49, up $1.92, or 3.73% since the insider transaction. Historical insider transactions for Ensign Group go as follows:

  • 4-Week # shares sold: 1,664
  • 12-Week # shares sold: 2,704
  • 24-Week # shares sold: 8,197

The average volume for Ensign Group has been 120,700 shares per day over the past 30 days. Ensign Group has a market cap of $1.3 billion and is part of the health care sector and health services industry. Shares are up 13.13% year-to-date as of the close of trading on Tuesday.

The Ensign Group, Inc., through its subsidiaries, provides skilled nursing and rehabilitative care services in the United States. It operates through two segments, Transitional, Skilled and Assisted Living Services; and Home Health and Hospice Services. The stock currently has a dividend yield of 0.6%. The company has a P/E ratio of 32.0. Currently, there are 5 analysts who rate Ensign Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENSG - FREE

TheStreet Quant Ratings rates Ensign Group as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Ensign Group Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings